Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1745-1753

  Lee, A Y ^a   Connors, J M ^a   Klimo, P ^a   O'Reilly, S E ^a   Gascoyne, R D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE COURSE; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030913592     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1745     Document Type: Article

References (40)

1. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
2. Hubbard SM, Chabner BA, DeVita VT, et al: Histologic progression in non-Hodgkin's lymphoma. Blood 59:258-264, 1982
3. Fisher RI, DeVita VT, Hubbard SM, et al: Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMace MOPP chemotherapy. Ann Intern Med 98:304-309, 1983
4. Coltman CA Jr, Dahlberg S, Jones SE, et al: CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: A twelve-year Southwest Oncology Group follow-up. Proc Am Soc Clin Oncol 5:197, 1986 (abstr 774)
5. Armitage JO, Cheson BD: Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 6:1335-1347, 1988
6. Shipp MA, Yeap BY, Harrington DP, et al: The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 8:84-93, 1990
7. Cabanillas F, Velasquez WS, Hagemeister FB, et al: Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood 79:1024-1028, 1992
8. Mackintosh FR, O'Neil M, Rosenberg SA: Prognostic factors in advanced histiocytic lymphoma. Proc Am Soc Clin Oncol 21:465, 1980 (abstr C-574)
9. Mead GM, Mackintosh FR, Burke JS, et al: Late relapse from complete remission in nodular and diffuse histiocytic lymphoma. Cancer 52:1356-1359, 1983
10. Head DR, Avakian J, Kjeldsberg CR, et al: Relapse of intermediate or high-grade (unfavorable) non-Hodgkin's lymphoma as a low grade (favorable) non-Hodgkin's lymphoma. Am J Clin Pathol 89:106-108, 1988
11. Kerrigan DP, Foucar K, Dressler L: High-grade non-Hodgkin lymphoma relapsing as low-grade follicular lymphoma: So-called downgraded lymphoma. Am J Hematol 30:36-41, 1989
12. Marazuela M, Yebra M, Girón JA, et al: Late relapse with nodular lymphoma after treatment for diffuse non-Hodgkin's lymphoma. Cancer 67:1950-1953, 1991
13. Dumontet C, Bastion Y, Felman P, et al: Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen. Ann Oncol 3:639-644, 1992
14. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
15. Klimo P, Connors JM: Updated clinical experience with MACOP-B. Semin Hematol 24:26-34, 1987 (suppl 1)
16. Connors JM, Klimo P: MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin Hematol 25:41-46, 1988 (suppl 2)
17. Hoskins PJ, Ng V, Spinelli JJ, et al: Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 9:220-226, 1991
18. Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
19. Krajewski S, Bodrug S, Gascoyne RD, et al: Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 145:515-525, 1994
20. Horsman DE, Gascoyne RD, Coupland RW, et al: Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphomas. Am J Clin Pathol 103:472-478, 1995
21. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
23. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 83:1165-1173, 1994
24. O'Brien CJ, Howard M, Child JA: Downgrading of non-Hodgkin's lymphoma following chemotherapy. Acta Haematol 77:57-59, 1987
25. Fisher RI, Jones RB, DeVita VT, et al: Natural history of malignant lymphomas with divergent histologies at staging evaluation. Cancer 47:2022-2025, 1981
26. Robertson LE, Redman JR, Butler JJ, et al: Discordant bone marrow involvement in diffuse large-cell lymphoma: A distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol 9:236-242, 1991
27. Aviles A, Narvaez BR, Diaz-Maqueo JC, et al: Value of serum beta 2 microglobulin as an indicator of early relapse in diffuse large cell lymphoma. Leuk Lymphoma 9:377-380, 1993
28. Blay JY, Burdin N, Rousset F, et al: Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor. Blood 82:2169-2174, 1993
29. Medeiros LJ, Gelb AB, Wolfson K, et al: Major histocompatibility complex class I and class II antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome. Am J Pathol 143:1086-1097, 1993
30. Offit K, Lo Coco F, Louie D, et al: Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 331:74-80, 1994
31. Stauder R, Eisterer W, Thaler J, et al: CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 85:2885-2899, 1995
32. Gascoyne R, Tolcher A, Coupland R, et al: The prognostic significance of immunophenotype in diffuse large cell lymphomas. Mod Pathol 7:109A, 1994 (abstr 629)
33. Aisenberg AC, Wilkes BM, Jacobson JO: The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 71:969-972, 1988
34. Gascoyne R, Adomat S, Tolcher A, et al: Prognostic relevance of the bcl-2 translocation in diffuse large cell lymphomas. Mod Pathol 7:109A, 1994 (abstr 630)
35. Kramer MHH, Hermans J, Parker J, et al: Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J Clin Oncol 14:2131-2138, 1996
36. Hill ME, MacLennan KA, Cunningham DC, et al: Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangements in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood 88:1046-1051, 1996
37. Pezzella F, Tse AGD, Cordell JL, et al: Expression of the bcl-2 oncogene protein is not specific for the 14; 18 chromosomal translocation. Am J Pathol 137:225-232, 1990
38. Akagi T, Kondo E, Yoshino T: Expression of bcl-2 protein and bcl-2 mRNA in normal and neoplastic lymphoid tissues. Leuk Lymphoma 13:81-87, 1994
39. Tang SC, Visser L, Hepperle B, et al: Clinical significance of bcl-2 MBR gene rearrangement and protein expression in diffuse large cell non-Hodgkin's lymphoma: An analysis of 83 cases. J Clin Oncol 12:149-154, 1994
40. Miller TP, Levy N, Bailey NP, et al: The bcl-2 gene translocation (t14; 18) identifies a subgroup of patients with diffuse large cell lymphoma (DLCL) having an indolent clinical course with late relapse. Proc Am Soc Clin Oncol 13:370, 1994 (abstr 1249)